120 related articles for article (PubMed ID: 2510586)
21. Evaluation of the ratio method compared with graphical analyses for estimating nigrostriatal function in human 18F-dopa PET studies with or without carbidopa.
Otsuka M; Ichiya Y; Kuwabara Y; Fukumura T; Sasaki M; Masuda K
Nucl Med Commun; 1993 Oct; 14(10):862-7. PubMed ID: 8233229
[TBL] [Abstract][Full Text] [Related]
22. Positron emission tomography in progressive supranuclear palsy.
Bhatt MH; Snow BJ; Martin WR; Peppard R; Calne DB
Arch Neurol; 1991 Apr; 48(4):389-91. PubMed ID: 1901484
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography in Shy-Drager syndrome.
Bhatt MH; Snow BJ; Martin WR; Cooper S; Calne DB
Ann Neurol; 1990 Jul; 28(1):101-3. PubMed ID: 2375624
[TBL] [Abstract][Full Text] [Related]
24. Involvement of the basal ganglia in refractory epilepsy: an 18F-fluoro-L-DOPA PET study using 2 methods of analysis.
Bouilleret V; Semah F; Biraben A; Taussig D; Chassoux F; Syrota A; Ribeiro MJ
J Nucl Med; 2005 Mar; 46(3):540-7. PubMed ID: 15750171
[TBL] [Abstract][Full Text] [Related]
25. Methanol intoxication-induced nigrostriatal dysfunction detected using 6-[18F]fluoro-L-dopa PET.
Airas L; Paavilainen T; Marttila RJ; Rinne J
Neurotoxicology; 2008 Jul; 29(4):671-4. PubMed ID: 18482768
[TBL] [Abstract][Full Text] [Related]
26. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions.
Vingerhoets FJ; Snow BJ; Tetrud JW; Langston JW; Schulzer M; Calne DB
Ann Neurol; 1994 Nov; 36(5):765-70. PubMed ID: 7979223
[TBL] [Abstract][Full Text] [Related]
27. PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium.
Yatham LN; Liddle PF; Shiah IS; Lam RW; Ngan E; Scarrow G; Imperial M; Stoessl J; Sossi V; Ruth TJ
Am J Psychiatry; 2002 May; 159(5):768-74. PubMed ID: 11986130
[TBL] [Abstract][Full Text] [Related]
28. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
29. Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations.
Tzoulis C; Tran GT; Schwarzlmüller T; Specht K; Haugarvoll K; Balafkan N; Lilleng PK; Miletic H; Biermann M; Bindoff LA
Brain; 2013 Aug; 136(Pt 8):2393-404. PubMed ID: 23625061
[TBL] [Abstract][Full Text] [Related]
30. Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects.
Kuwabara H; Cumming P; Reith J; Léger G; Diksic M; Evans AC; Gjedde A
J Cereb Blood Flow Metab; 1993 Jan; 13(1):43-56. PubMed ID: 8417009
[TBL] [Abstract][Full Text] [Related]
31. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study.
Khan NL; Brooks DJ; Pavese N; Sweeney MG; Wood NW; Lees AJ; Piccini P
Brain; 2002 Oct; 125(Pt 10):2248-56. PubMed ID: 12244082
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow.
Bhatt MH; Snow BJ; Martin WR; Pate BD; Ruth TJ; Calne DB
Ann Neurol; 1991 Jun; 29(6):673-7. PubMed ID: 1892369
[TBL] [Abstract][Full Text] [Related]
33. Age-related changes in the human nigrostriatal dopaminergic system.
De Keyser J; Ebinger G; Vauquelin G
Ann Neurol; 1990 Feb; 27(2):157-61. PubMed ID: 2107785
[TBL] [Abstract][Full Text] [Related]
34. Aging and the nigrostriatal dopamine system: a non-human primate study.
Irwin I; DeLanney LE; McNeill T; Chan P; Forno LS; Murphy GM; Di Monte DA; Sandy MS; Langston JW
Neurodegeneration; 1994 Dec; 3(4):251-65. PubMed ID: 7531106
[TBL] [Abstract][Full Text] [Related]
35. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease.
Kas A; Bottlaender M; Gallezot JD; Vidailhet M; Villafane G; Grégoire MC; Coulon C; Valette H; Dollé F; Ribeiro MJ; Hantraye P; Remy P
J Cereb Blood Flow Metab; 2009 Sep; 29(9):1601-8. PubMed ID: 19491921
[TBL] [Abstract][Full Text] [Related]
36. Validation of the three-dimensional acquisition mode in positron emission tomography for the quantitation of [18F]fluoro-DOPA uptake in the human striata.
Trébossen R; Bendriem B; Ribeiro MJ; Fontaine A; Frouin V; Remy P
J Cereb Blood Flow Metab; 1998 Sep; 18(9):951-9. PubMed ID: 9740098
[TBL] [Abstract][Full Text] [Related]
37. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices.
Pate BD; Kawamata T; Yamada T; McGeer EG; Hewitt KA; Snow BJ; Ruth TJ; Calne DB
Ann Neurol; 1993 Sep; 34(3):331-8. PubMed ID: 8363350
[TBL] [Abstract][Full Text] [Related]
38. The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates.
Pate BD; Snow BJ; Hewitt KA; Morrison KS; Ruth TJ; Calne DB
J Nucl Med; 1991 Jun; 32(6):1246-51. PubMed ID: 1904482
[TBL] [Abstract][Full Text] [Related]
39. Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant Kocc and the [18F]fluorodopa plasma input uptake rate constant Ki.
Sossi V; Holden JE; de la Fuente-Fernandez R; Ruth TJ; Stoessl AJ
J Cereb Blood Flow Metab; 2003 Mar; 23(3):301-9. PubMed ID: 12621305
[TBL] [Abstract][Full Text] [Related]
40. Delayed L-phenylalanine infusion allows for simultaneous kinetic analysis and improved evaluation of specific-to-nonspecific fluorine-18-dopa uptake in brain.
Doudet DJ; McLellan CA; Aigner TG; Wyatt RJ; Cohen RM
J Nucl Med; 1992 Jul; 33(7):1383-9. PubMed ID: 1613582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
